Safety, tolerability and mechanism of action of boswellic acids (BOSWELAN) in multiple sclerosis and clinically isolated syndrome
Relapsing Remitting Multiple Sclerosis
Enrolment: 29 · Results not recorded
Loading the evidence…
Nutraceutical
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Relapsing Remitting Multiple Sclerosis
Enrolment: 29 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Kainic acid-induced excitotoxic hippocampal injury (15 mg/kg intraperitoneally); hippocampal synaptosome glutamate release in vitro
11-Keto-beta-boswellic acid dose-dependently inhibited 4-aminopyridine-stimulated glutamate release in a calcium-dependent, vesicular manner, and pretreatment considerably ameliorated the kainic acid-induced rise in glutamate and CA3 neuronal death.
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.